An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Trial Profile

An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Ecopipam (Primary)
  • Indications Self-injurious behaviour
  • Focus Therapeutic Use
  • Sponsors Psyadon Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Oct 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-002662-12).
    • 29 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top